{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:38:36Z","timestamp":1782419916559,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID\u2010axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The RAPID\u2010axSpA (NCT01087762) trial is double\u2010blind and placebo\u2010controlled to week 24, dose\u2010blind to week 48, and open\u2010label to week 204. Patients were randomized to certolizumab pegol (CZP) or placebo. Placebo patients entering the dose\u2010blind phase were re\u2010randomized to CZP. Uveitis events were recorded on extraarticular manifestation or adverse event forms. Events were analyzed in patients with\/without history of uveitis, and rates reported per 100 patient\u2010years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, 38 of 218 CZP\u2010randomized patients (17.4%) and 31 of 107 placebo\u2010randomized patients (29.0%) had past uveitis history. During the 24\u2010week double\u2010blind phase, the rate of uveitis flares was lower in CZP (3.0 [95% confidence interval (95% CI) 0.6\u20138.8] per 100 patient\u2010years) than in placebo (10.3 [95% CI 2.8\u201326.3] per 100 patient\u2010years). All cases observed during the 24\u2010week double\u2010blind phase were in patients with a history of uveitis; in these patients, rates were similarly lower for CZP (17.1 [95% CI 3.5\u201350.1] per 100 patient\u2010years) than placebo (38.5 [95% CI 10.5\u201398.5] per 100 patient\u2010years). Rates of uveitis flares remained low up to week 96 (4.9 [95% CI 3.2\u20137.4] per 100 patient\u2010years) and were similar between AS (4.4 [95% CI 2.3\u20137.7] per 100 patient\u2010years) and nr\u2010axial SpA (5.6 [95% CI 2.9\u20139.8] per 100 patient\u2010years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rate of uveitis flares was lower for axial SpA patients treated with CZP than placebo during the randomized controlled phase. Incidence of uveitis flares remained low to week 96 and was comparable to rates reported for AS patients receiving other anti\u2013tumor necrosis factor antibodies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.22848","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T15:14:14Z","timestamp":1453907654000},"page":"838-844","source":"Crossref","is-referenced-by-count":87,"title":["Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis"],"prefix":"10.1002","volume":"68","author":[{"given":"M.","family":"Rudwaleit","sequence":"first","affiliation":[{"name":"Klinikum Bielefeld  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Devers Eye Institute, Legacy Health System, Portland, Oregon, and Oregon Health &amp; Science University Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Academic Medical Center, Amsterdam and Atrium Medical Center Heerlen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Marzo\u2010Ortega","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sieper","sequence":"additional","affiliation":[{"name":"University Hospital Charit\u00e9 Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Davies","sequence":"additional","affiliation":[{"name":"UCB Pharma Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bartz","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nurminen","sequence":"additional","affiliation":[{"name":"UCB Pharma Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.08.010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21688"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"e_1_2_8_5_1","first-page":"S143","article-title":"Anti\u2010TNF therapy for eye involvement in spondyloarthropathy","volume":"20","author":"Rosenbaum J","year":"2002","journal-title":"Clin Exp Rheum"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.01.013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X12458372"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.43"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.6.841"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0489-2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-69459-5_2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2000.84"},{"key":"e_1_2_8_13_1","first-page":"81","article-title":"Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine","volume":"60","author":"Dougados M","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.198"},{"key":"e_1_2_8_15_1","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one\u2010year period [abstract]","volume":"30","author":"Munoz\u2010Fernandez S","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-30798-3_12"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103192"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092585"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.1558"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.967779"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/286857"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"e_1_2_8_25_1","first-page":"437","article-title":"Fiducial limits for the Poisson distribution","volume":"28","author":"Garwood F.","year":"1936","journal-title":"Biometrika"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130588"},{"key":"e_1_2_8_27_1","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen A","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203419"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01292-7"},{"key":"e_1_2_8_32_1","article-title":"Decreased recurrence rate of anterior uveitis in ankylosing spondylitis treated with adalimumab: an interim analysis [abstract]","volume":"62","author":"Horst\u2010Bruinsma I","year":"2010","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_33_1","first-page":"2667","article-title":"Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors","volume":"28","author":"Brophy S","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_34_1","first-page":"S10","article-title":"Acute anterior uveitis in ankylosing spondylitis: association with inflammatory bowel disease and psoriasis independent of HLA\u2013B27 [abstract]","volume":"67","author":"Omar S","year":"2015","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22848","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.22848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:34Z","timestamp":1759419094000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/acr.22848"],"URL":"https:\/\/doi.org\/10.1002\/acr.22848","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}